Briacell Acquiring, Expanding, Developing, On ScheduleThe CEO has major "skin" in the game - acquiring 5.4 mil share at .24c. That itself is impressive. The Phase I/IIa clinical trial for the Briavax vaccine is continuing as per schedule. They are on track to have 10 patients by end of September. Acquired Sapientia Pharma with 2x US patents and the proprietary technology of "PKCd", Protein Kinase C delta. On-board 2x PhD Dr.'s / Scientists / Researchers who are highly sought after in the oncology / drug development industry. These guys are going to attract some big time attention working with Briacell. Don't say I didn't warn you. jmo.